Walvax (SHE: 300142) recently formed a strategic collaboration with Honeywell (Nasdaq: HON) that led to the construction of China’s first mRNA COVID-19 vaccine production plant.
The company has been working since 2017 to become a leading vaccine R&D company, recounted Shawn Opatka, vice president, life sciences, Honeywell Process Solutions. “Their goals accelerated the construction of a digital-enabled center for vaccine production, and vision for a smart factory,” he said.
When building the mRNA vaccine plan, Walvax used Honeywell’s intelligent plant technology to enable the digital production and operation of the smart plant.
First, the companies collaborated on deploying a supervisory control and data acquisition (SCADA) system pilot for other projects. “Since then, H…